Lyell Immunopharma Inc. (LYEL)
Lyell Immunopharma Statistics
Share Statistics
Lyell Immunopharma has 295.23M shares outstanding. The number of shares has increased by 15.8% in one year.
Shares Outstanding | 295.23M |
Shares Change (YoY) | 15.8% |
Shares Change (QoQ) | 1.05% |
Owned by Institutions (%) | 58.63% |
Shares Floating | 124.87M |
Failed to Deliver (FTD) Shares | 695 |
FTD / Avg. Volume | 0.07% |
Short Selling Information
The latest short interest is 12.4M, so 4.24% of the outstanding shares have been sold short.
Short Interest | 12.4M |
Short % of Shares Out | 4.24% |
Short % of Float | 8.22% |
Short Ratio (days to cover) | 10.75 |
Valuation Ratios
The PE ratio is -0.49 and the forward PE ratio is -1.35. Lyell Immunopharma's PEG ratio is -0.01.
PE Ratio | -0.49 |
Forward PE | -1.35 |
PS Ratio | 2743.4 |
Forward PS | 2735.3 |
PB Ratio | 0.44 |
P/FCF Ratio | -1.03 |
PEG Ratio | -0.01 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Lyell Immunopharma.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.06, with a Debt / Equity ratio of 0.13.
Current Ratio | 7.06 |
Quick Ratio | 7.06 |
Debt / Equity | 0.13 |
Debt / EBITDA | -15.41 |
Debt / FCF | -0.31 |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $203.33 |
Profits Per Employee | $-1.14M |
Employee Count | 300 |
Asset Turnover | 0 |
Inventory Turnover | n/a |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -75.24% in the last 52 weeks. The beta is -0.42, so Lyell Immunopharma's price volatility has been lower than the market average.
Beta | -0.42 |
52-Week Price Change | -75.24% |
50-Day Moving Average | 0.61 |
200-Day Moving Average | 1.07 |
Relative Strength Index (RSI) | 41.63 |
Average Volume (20 Days) | 1.03M |
Income Statement
In the last 12 months, Lyell Immunopharma had revenue of 61K and earned -342.99M in profits. Earnings per share was -1.31.
Revenue | 61K |
Gross Profit | 61K |
Operating Income | -3.31M |
Net Income | -342.99M |
EBITDA | -3.31M |
EBIT | n/a |
Earnings Per Share (EPS) | -1.31 |
Balance Sheet
The company has 105.6M in cash and 50.99M in debt, giving a net cash position of 54.6M.
Cash & Cash Equivalents | 105.6M |
Total Debt | 50.99M |
Net Cash | 54.6M |
Retained Earnings | -1.35B |
Total Assets | 490.86M |
Working Capital | 325.81M |
Cash Flow
In the last 12 months, operating cash flow was -162.39M and capital expenditures -464K, giving a free cash flow of -162.86M.
Operating Cash Flow | -162.39M |
Capital Expenditures | -464K |
Free Cash Flow | -162.86M |
FCF Per Share | -0.62 |
Margins
Gross margin is 100%, with operating and profit margins of -5424.59% and -562285.25%.
Gross Margin | 100% |
Operating Margin | -5424.59% |
Pretax Margin | -562285.25% |
Profit Margin | -562285.25% |
EBITDA Margin | -5424.59% |
EBIT Margin | -5424.59% |
FCF Margin | -266980.33% |
Dividends & Yields
LYEL does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for LYEL is $1, which is 96.1% higher than the current price. The consensus rating is "Hold".
Price Target | $1 |
Price Target Difference | 96.1% |
Analyst Consensus | Hold |
Analyst Count | 2 |
Scores
Altman Z-Score | -3.73 |
Piotroski F-Score | 2 |